

Nicholas Turner, MD MHSc Assistant Professor Division of Infectious Diseases DOTS Trial: Dalbavancin as an Option for Treatment of Staphylococcus aureus Bacteremia

Dr Turner completed a combined residency in Internal Medicine & Pediatrics, followed by an infectious diseases fellowship at Duke University. As an ARLG research fellow during the last 2 years of his infectious diseases training, he completed a Master's in Clinical Research – modeling the evolving epidemiology of C. difficile across a network of regional hospitals for his thesis. As a true ID generalist, he maintains diverse clinical and research roles – including serving as Associate State TB Controller for North Carolina, as an epidemiologist for the Duke Infection Control Outreach Network, a sub-investigator on a CDC Epicenters grant studying C. difficile prevention measures, and as an ARLG Trialist in Training currently involved in several ongoing clinical trials (including rapid penicillin allergy assessment, dalbavancin for S. aureus bacteremia, and COVID therapeutics).